These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 22393101)

  • 1. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
    Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
    Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
    Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
    Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ductal carcinoma in situ, complexities and challenges.
    Leonard GD; Swain SM
    J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
    Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
    J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.
    Guerrieri-Gonzaga A; Lazzeroni M; Botteri E; Serrano D; Rotmensz N; Varricchio MC; Cazzaniga M; Bollani G; Mora S; Montefrancesco C; Pruneri G; Viale G; Intra M; Galimberti V; Goldhirsch A; Bagnardi V; Bonanni B; DeCensi A
    Ann Oncol; 2013 Jul; 24(7):1859-1866. PubMed ID: 23532115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen Initiation After Ductal Carcinoma In Situ.
    Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
    Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
    Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
    Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
    Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
    Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of systemic therapy following ductal carcinoma in situ.
    Eng-Wong J; Costantino JP; Swain SM
    J Natl Cancer Inst Monogr; 2010; 2010(41):200-3. PubMed ID: 20956830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen in ductal carcinoma in situ.
    Daly MB
    Semin Oncol; 2006 Dec; 33(6):647-9. PubMed ID: 17145343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
    Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Land S; Mamounas E; Dignam J; Fisher ER; Wolmark N
    Semin Oncol; 2001 Aug; 28(4):400-18. PubMed ID: 11498833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
    van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
    Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
    Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
    J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast.
    Lo AC; Truong PT; Wai ES; Nichol A; Weir L; Speers C; Hayes MM; Baliski C; Tyldesley S
    Ann Oncol; 2015 Sep; 26(9):1898-1903. PubMed ID: 26063632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
    Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
    Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.